DDInter1021 DDInter899
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Lanreotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromocriptine
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurasidone
Lanreotide {u} may lead to a major life threatening interaction when taken with {v} Lonafarnib
Lanreotide {u} may lead to a major life threatening interaction when taken with {v} Copper oxodotreotide Cu-64
Lanreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Lanreotide may lead to a major life threatening interaction when taken with Lonafarnib
Lanreotide may lead to a major life threatening interaction when taken with Copper oxodotreotide Cu-64